Table 1.

Different parts of extracted criteria for decision-making assessment.

Part	Criteria	Reference
1-economical	1-economic evaluation guidelines by manufacturer 2-ICER thresholds 3-Budget impact 4-Expected budget increase for third party payer 5-Price in comparison to comparator drug 6-Sales volume of drug 7-Physicians demand	(19,20) (21-25) (21,26,27) (28,29) (30,31) (32) (33)
2- clinical	1-Considered RCT evidence 2-DALY as an endpoint of drug 3-Efficacy as a therapeutic value 4-Availability of treatment alternative 5-Condition is life threatening 6-Target population 7-Ability to reduce own health risk	(19,21,24,28,34,35) (24,34) (30,36,37) (21,24,26,38) (28,36,38) (24) (24)
3-study quality	1-Quality of evidence 2-Quality of economic model 3-Quality of economic evidence review of stakeholder perspectives 4-Degree of uncertainty 5-Consideration of HTA 6-Year of study publication	(27,39) (24,28,35,40) (24,28,35,40) (24,28,35,40) (26,28,38) (19,41) (24)
4-management field	1-rule of rescue 2-Ensure the availability of drugs 3-Place in therapeutic strategy (e.g. 1st or 2nd line treatment) 4-Objective of technology (e.g. prevention) 5-Objective of technology (e.g. treatment) 6-Expert Committee Decision	(42) (32) (36) (24,38) (24,38) (43,44)